13% Of patients with metachronous disease developed metastases within 24 mo after the diagnosis of primary BC; these patients were assumed to have received an AI shortly before developing metastases and therefore were not eligible for ET combined with CDK4/6 inhibitor as second-line ET. The gene discussed is CDK4; the disease is breast cancer.